The Conversation (0)
CEO Interviews
Featured Articles and Interviews
Press Releases
INNspired
Overview
BriaCell Therapeutics (NASDAQ:BCTX, BCTXW;TSX:BCT) is a clinical-phase biotechnology company developing innovative immunotherapies for treating cancer.
At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. A report released by Research and Markets says the global immuno-oncology market is expected to reach US$135 billion by 2024. BriaCell continues to uncover opportunities in this space with its innovative technologies.
BriaCell Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
*Disclaimer: This profile is sponsored by BriaCell ( TSX:BCT ). This profile provides information which was sourced by the Investing News Network (INN) and approved by BriaCell in order to help investors learn more about the company. BriaCell is a client of INN. The company's campaign fees pay for INN to create and update this profile.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with BriaCell and seek advice from a qualified investment advisor.
BriaCell Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects